A pilot and feasibility study comparing vaginal continence devices and pelvic floor muscle training (PFMT) versus PFMT only for female stress urinary incontinence

ISRCTN ISRCTN67752226
DOI https://doi.org/10.1186/ISRCTN67752226
IRAS number 334827
Secondary identifying numbers CPMS 68464, HIPS/23/30
Submission date
12/05/2025
Registration date
13/05/2025
Last edited
13/05/2025
Recruitment status
Recruiting
Overall study status
Ongoing
Condition category
Urological and Genital Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
Urinary incontinence (UI) is a common and distressing condition that affects over 6 million women in the UK who are over 40 years old. It can cause embarrassment, low self-esteem, social isolation, and reduced productivity. The first treatment option is pelvic floor muscle training (PFMT), but one in three women still need surgery. Vaginal continence devices (VCDs), which are worn inside the vagina, help support the bladder to achieve continence. Guidelines suggest using VCDs when PFMT alone is not effective. Combining VCDs with PFMT might be more effective than PFMT alone, improving quality of life and reducing the need for surgery. However, there is little evidence about the benefits, risks, and cost-effectiveness of VCDs. This study aims to provide such evidence through a preliminary study to ensure a larger clinical trial is feasible.

Who can participate?
Women with urinary incontinence from four to six hospitals in the UK will be invited to participate.

What does the study involve?
Participants will be divided into two groups: one group will receive PFMT alone, and the other group will receive PFMT combined with VCDs. Each participant has an equal chance of being in either group. Information on symptoms and quality of life will be collected before and after treatment at 3 and 6 months.

What are the possible benefits and risks of participating?
Participants may not benefit personally from taking part. By taking part, however, they may be helping us to inform the treatment of future women with stress urinary incontinence. The results of this study will help us plan a larger study, which in turn will help plan effective services offered by the NHS in the future. We do not think that there are any possible disadvantages to participants. All procedures and techniques are already being used in the NHS to treat patients with stress urinary incontinence. Taking part in the FEEL-GOOD study will help us assess these procedures and should not involve any additional risk to you.
Whichever group participants are in, their treatments will be offered by competent and trained clinicians.
It is important to remember that there are risks related with every treatment. Participants will be informed of any potential risks as part of their routine clinical care. Steps are always taken to ensure that these risks are kept to a minimum. The known side effects associated with pelvic floor muscle training and vaginal continence devices (which are not related to taking part in the study) are:
• pelvic floor muscle discomfort,
• low back pain,
• tummy pain/ discomfort,
• vaginal pain/ discomfort/ irritation,
• the vaginal device coming out on its own,
• vaginal discharge,
• unexpected vaginal bleeding or bleeding when removing the device
• urinary or vaginal infections,
• unable to pass urine which requires catheter in the bladder
If it is the wrong size, the vaginal continence device might fall out. If this happens participants can try a different size or type of device

Where is the study run from?
University of Aberdeen (UK)

When is the study starting and how long is it expected to run for?
April 2025 to May 2026

Who is funding the study?
Chief Scientist Office (UK)

Who is the main contact?
uzunma.onyeakazi1@abdn.ac.uk

Contact information

Prof Mohamed Abdel-Fattah
Principal Investigator

Aberdeen Maternity Hospital
Aberdeen
AB25 2ZH
United Kingdom

Email abdelfattah@abdn.ac.uk
Ms Uzunma Onyeakazi
Public, Scientific

Centre for Healthcare Randomised Trials (CHaRT), Health Sciences Building, Foresterhill, University of Aberdeen
Aberdeen
AB25 2ZD
United Kingdom

Phone +44 1224 438181
Email uzunma.onyeakazi1@abdn.ac.uk

Study information

Study designInterventional randomized controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Other
Study typeTreatment
Participant information sheet 47322 PIL_Main study v3 10 April 2025_clean.pdf
Scientific titleFEEL-GOOD study: Female Empowerment through Enhanced Living: a comparison of vaGinal continence devices and pelvic flOOr muscle training (PFMT) versus PFMT only for female stress urinary incontinence: a feasibility and pilot StuDy. Stage 2
Study objectivesThe aim of the study is to determine the feasibility to deliver a definitive RCT comparing the clinical and cost-effectiveness of Vaginal Continence Devices (VCDs) and Pelvic Floor Muscle Training (PMFT) compared to PFMT only in the conservative management of stress-predominant urinary incontinence (SUI) in women. The objectives include: (i) To establish the facilitators and barriers for recruitment (and specifically randomisation) for women and healthcare providers for a definitive RCT. (ii) To establish the relevant outcomes for a definitive RCT from women’s and healthcare professionals’ (HCPs) perspectives. (iii) To establish a reliable sample size and recruitment projection for a definitive RCT, the adherence of participants to the proposed treatments, response rates to questionnaires, and loss to follow-up rate.
Ethics approval(s)

Approved 27/03/2025, South Central - Hampshire A Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 207 1048135; hampshirea.rec@hra.nhs.uk), ref: 25/SC/0077

Health condition(s) or problem(s) studiedFemale stress urinary incontinence
InterventionWomen will be provided with information about the study, and if the agree, they will be asked to sign a consent form confirming this and to complete a baseline questionnaire that asks about their quality of life, their symptoms, the impact of these symptoms on their daily life. A member of the research team will complete a case report form with some baseline information about the participant. Then, the participant will be randomised to one of two groups (i) vaginal continence devices and supervised pelvic floor muscle training and (ii) supervised pelvic floor muscle training alone. Whichever group they are in, they will be added to the waiting list for pelvic floor muscle training. In the group randomised to have vaginal continence devices, the clinician will request the participant's GP to prescribe the VCD. This will be prescribed and/or they will start using their VCDs at the time (or as close as practically possible) to their first physiotherapy appointment.

We will follow women up with questionnaires (which they can complete by post or electronically) after they have been in the study for 3 and 6 months. These questionnaires will contain similar questions to those they completed at baseline, and also ask about any adverse events they have experienced since joining the study.

At at least one of the sites, we will seek to audio-record the initial consultations between HCPs and potential participants where trial participation is discussed. We will ask participants if they want to take part in an interview about their experience in the study, including any motivation to take part. We will also invite women who decide not to take part in the main study if they would like to be interviewed about their decision not to take part in the study.
Intervention typeMixed
Primary outcome measureFeasibility of participant recruitment within the proposed time scale (I.e. achieve >/= 80% of the target recruitment within 6 months)
Secondary outcome measures1. Adherence to VCD use is measured using clinician-reported adherence logs and participant self-report diaries at baseline, 3 months, and 6 months
2. Adherence to PFMT is measured using participant self-reported attendance logs to individualised planned program appointments at baseline, 3 months, and 6 months
3. Retention rate is measured using study records of participant completion status at 6 months
4. Rates of missing data are measured using case report forms and electronic data capture system audit logs at baseline, 3 months, and 6 months
5. Patient-reported success rates of VCDs are measured using the Patient Global Impression of Improvement (PGI-I) scale at 3 months and 6 months
6. Adverse events related to VCDs are measured using adverse event reporting forms and participant interviews at baseline, 3 months, and 6 months
7. Use of self-funded VCDs is measured using participant self-report questionnaires at baseline, 3 months, and 6 months
8. Waiting times for physiotherapy are measured using clinic administrative records and participant self-report at baseline and 3 months
9. Recruitment projection reliability is measured using screening and enrolment logs compared to projected targets at monthly intervals throughout the recruitment period
10. Refinement of pre-defined progression criteria for a potential future RCT is measured using feasibility study outcomes and stakeholder feedback at study end (6 months)
Overall study start date01/04/2025
Completion date31/05/2026

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexFemale
Target number of participantsPlanned Sample Size: 74; UK Sample Size: 74
Key inclusion criteria1. Women aged 18 years or over with clinically diagnosed stress predominant UI and deemed by their clinician to be suitable for VCDs, and willing to self-manage VCDs.
2. Inclusion criteria for the health care professionals invited to take part in a focus group are: clinicians, physiotherapists and specialist nurses in the pilot sites who are involved in the care of women with stress predominant SUI.
Key exclusion criteria1. Vaginal prolapse more than POP-Q Stage 2a (POP-Q= Pelvic Organ Prolapse Quantification score)
2. Neurogenic bladder
3. Urgency predominant UI
4. Evidence of active pelvic or vaginal infection
5. Vaginal ulceration
6. Allergy to silicone or rubber
7. Known vaginal cancer
8. Current pregnancy or within 6 months postpartum
9. Completed full course of supervised Pelvic Floor Muscle Training and has been discharged by the physiotherapist within the last two years
10. Contraindications to vaginal devices:
10.1. Current vaginal infection or irritation
10.2. History of Toxic Shock Syndrome
10.3. Pelvic surgery in the last 6 months
10.4. Ongoing therapy for pelvic malignancy
10.5. Current urinary infection
10.6. Problems with manual dexterity which could cause insertion or removal issues
11. Women lacking capacity to consent
12. Inability to understand the PIL, consent and/or questionnaires in English
Date of first enrolment06/05/2025
Date of final enrolment07/10/2025

Locations

Countries of recruitment

  • United Kingdom

Study participating centres

NHS Grampian
Summerfield House
2 Eday Road
Aberdeen
AB15 6RE
United Kingdom
Leeds Teaching Hospitals NHS Trust
St. James's University Hospital
Beckett Street
Leeds
LS9 7TF
United Kingdom
Countess of Chester Hospital
Countess of Chester Health Park
Liverpool Road
Chester
CH2 1UL
United Kingdom
Huddersfield Royal Infirmary
Calderdale & Huddersfield NHS Trust
Acre Street
Huddersfield
HD3 3EA
United Kingdom
St Mary's Hospital
Manchester University NHS Foundation Trust
Oxford Road
Manchester
M13 9WL
United Kingdom
Queen Elizabeth University Hospital
1345 Govan Road
Glasgow
G51 4TF
United Kingdom

Sponsor information

University of Aberdeen
University/education

Research Governance Office, First Floor, Health Sciences Building, Foresterhill
Aberdeen
AB25 2ZD
Scotland
United Kingdom

Phone +44 1224437221
Email researchgovernance@abdn.ac.uk
Website https://www.abdn.ac.uk
ROR logo "ROR" https://ror.org/016476m91

Funders

Funder type

Government

Chief Scientist Office
Government organisation / Local government
Alternative name(s)
CSO
Location
United Kingdom

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryData sharing statement to be made available at a later date
Publication and dissemination planPlanned publication in a peer-reviewed journal
IPD sharing planThe current data sharing plans for this study are unknown and will be available at a later date

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Participant information sheet version 3 10/04/2025 13/05/2025 No Yes

Additional files

47322 PIL_Main study v3 10 April 2025_clean.pdf

Editorial Notes

12/05/2025: Trial's existence confirmed by the National Institute for Health and Care Research (NIHR) (UK).